Journal: Epidemiologic Reviews

Article Title: CEPI: Driving Progress Toward Epidemic Preparedness and Response

doi: 10.1093/epirev/mxz012

Figure Lengend Snippet: Coalition for Epidemic Preparedness Innovations Vaccine-Development Partnerships up to March 2019

Article Snippet: Profectus Biosciences, Emergent, and PATH , $25 million to develop a recombinant subunit protein vaccine against Nipah virus , May 2018.

Techniques: Bioprocessing, Virus, Plasmid Preparation, Recombinant, Modification, Clinical Proteomics, Immunopeptidomics, Vaccines

Journal: Virus Research

Article Title: COVID-19 Vaccine: A comprehensive status report

doi: 10.1016/j.virusres.2020.198114

Figure Lengend Snippet: Outline of the vaccine production platforms for SARS-CoV-2 and their advantages and limitations

Article Snippet: 4 , Recombinant protein Subunit vaccine/Influenza, SARS-CoV/ ( ) ( ) ( ) , Sanofi , Pre-Clinical , It is a recombinant vaccine of unrevealed SARS-CoV-2 protein(s) which is expressed in baculovirus vector system..

Techniques: Virus, Derivative Assay, Immunopeptidomics, Plasmid Preparation, Vaccines

Journal: Virus Research

Article Title: COVID-19 Vaccine: A comprehensive status report

doi: 10.1016/j.virusres.2020.198114

Figure Lengend Snippet: Pie Chart showing the different categories of SARS-CoV-2 vaccines under research .

Article Snippet: 4 , Recombinant protein Subunit vaccine/Influenza, SARS-CoV/ ( ) ( ) ( ) , Sanofi , Pre-Clinical , It is a recombinant vaccine of unrevealed SARS-CoV-2 protein(s) which is expressed in baculovirus vector system..

Techniques: Vaccines

Journal: Virus Research

Article Title: COVID-19 Vaccine: A comprehensive status report

doi: 10.1016/j.virusres.2020.198114

Figure Lengend Snippet: Rapidly progressing Anti COVID-19 vaccines. This table contains the information of rapidly developing vaccine candidates only, the list of all vaccine candidates in the pipeline can be accessed from: https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bip

Article Snippet: 4 , Recombinant protein Subunit vaccine/Influenza, SARS-CoV/ ( ) ( ) ( ) , Sanofi , Pre-Clinical , It is a recombinant vaccine of unrevealed SARS-CoV-2 protein(s) which is expressed in baculovirus vector system..

Techniques: Vaccines, Plasmid Preparation, Clinical Proteomics, Construct, Immunopeptidomics, Isolation, Modification, Virus, Expressing, Recombinant, Functional Assay, Combined Bisulfite Restriction Analysis Assay, Purification, Animal Model, Adjuvant, Produced, Sequencing, Infection, Avidin-Biotin Assay

Journal: Vaccines

Article Title: A Narrative Review of COVID-19 Vaccines

doi: 10.3390/vaccines10010062

Figure Lengend Snippet: Schematic drawing of SARS-CoV-2 representing the major virus components: spike glycoprotein (S), hemagglutinin-esterase dimer (HE), membrane protein (M), envelope protein (E), nucleocapsid, and genomic RNA. (Redrawn by the authors based on Figure 2 in Ref. ).

Article Snippet: 83 , SARS-CoV-2 Protein Subunit Recombinant Vaccine , Biofarma , Protein subunit , Indonesia , 1/2 , NCT05067894 , Indonesia , 780 , November 2021–March 2022 , Safety (phase I) and immunogenicity (phase II) of the SARS-CoV-2 protein subunit recombinant vaccine..

Techniques:

Journal: Vaccines

Article Title: A Narrative Review of COVID-19 Vaccines

doi: 10.3390/vaccines10010062

Figure Lengend Snippet: SARS CoV-2 life cycle: (1) Binding and viral entry to the host cell via endocytosis; (2) release of viral genome; (3) translation and (4) replication of RNA genome; (5) transcription and translation of RNA into protein; (6) assembly and budding, followed by (7) mature virion formation; and (8) release of the new virion from the host cell. (Redrawn by the authors based on second figure in Ref. ).

Article Snippet: 83 , SARS-CoV-2 Protein Subunit Recombinant Vaccine , Biofarma , Protein subunit , Indonesia , 1/2 , NCT05067894 , Indonesia , 780 , November 2021–March 2022 , Safety (phase I) and immunogenicity (phase II) of the SARS-CoV-2 protein subunit recombinant vaccine..

Techniques: Binding Assay

Journal: Vaccines

Article Title: A Narrative Review of COVID-19 Vaccines

doi: 10.3390/vaccines10010062

Figure Lengend Snippet: COVID-19 vaccine candidates in phase 1–3 clinical trial as per 15 November 2021 [ 56 ].

Article Snippet: 83 , SARS-CoV-2 Protein Subunit Recombinant Vaccine , Biofarma , Protein subunit , Indonesia , 1/2 , NCT05067894 , Indonesia , 780 , November 2021–March 2022 , Safety (phase I) and immunogenicity (phase II) of the SARS-CoV-2 protein subunit recombinant vaccine..

Techniques: Plasmid Preparation, Injection, Infection, Recombinant, Polymerase Chain Reaction, Plaque Reduction Neutralization Test, Variant Assay, Binding Assay, Coagulation, Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, Pregnancy Test (hCG) Assay

Journal: Applied Microbiology and Biotechnology

Article Title: Current view on novel vaccine technologies to combat human infectious diseases

doi: 10.1007/s00253-021-11713-0

Figure Lengend Snippet: Ongoing clinical trials for novel vaccine compounds against infectious diseases in humans in phases 1–3 listed by the FDA by the November 1, 2021 ( https://www.clinicaltrials.gov/ )

Article Snippet: COVID-19 , NCT04760743 , 2020-12-17 , Recombinant Spike protein subunit vaccine , I (P) , SK bioscience Co., Ltd.

Techniques: Clinical Proteomics, Control, Recombinant, Produced, Synthesized, Plasmid Preparation, Liposomes, Vaccines